Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announced the granting... View Article
Author Archives for Adeline Chauvigné
Pherecydes Pharma continues to strengthen its intellectual property with a first patent granted in China
5 May 2024Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announced the granting... View Article
New member | AbolerIS Pharma
AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in... View Article
New member | AbolerIS Pharma
5 May 2024AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in... View Article
New member | THERADEV
THERADEV develops solutions composed of phytogenic active ingredients for the prevention of metabolic diseases. Find out more about THERADEV: www.theradev.fr
New member | THERADEV
5 May 2024THERADEV develops solutions composed of phytogenic active ingredients for the prevention of metabolic diseases. Find out more about THERADEV: www.theradev.fr
New member | Theradev
Theradev specialises in the research and development of innovative solutions for the regulation of major metabolic disorders. Thanks to its... View Article
New member | Theradev
5 May 2024Theradev specialises in the research and development of innovative solutions for the regulation of major metabolic disorders. Thanks to its... View Article
ABYS® MEDICAL successfully completes its first Series A of €3 million
Abys® Medical, deeptech creator of the Surgery 4.0 concept, finalized in August 2021 a fundraising by opening its capital to... View Article
ABYS® MEDICAL successfully completes its first Series A of €3 million
5 May 2024Abys® Medical, deeptech creator of the Surgery 4.0 concept, finalized in August 2021 a fundraising by opening its capital to... View Article
Valneva confirms initiation of rolling review with EMA and provides updates on its COVID-19 vaccine program VLA2001
Valneva, a specialty vaccine company, today confirmed that the European Medicines Agency (EMA) has started a rolling review of VLA2001,... View Article
Valneva confirms initiation of rolling review with EMA and provides updates on its COVID-19 vaccine program VLA2001
5 May 2024Valneva, a specialty vaccine company, today confirmed that the European Medicines Agency (EMA) has started a rolling review of VLA2001,... View Article
New member | Healshape
Healshape is a regenerative medicine company with the mission to offer the enhanced option of self-tissue regeneration from patient’s own... View Article
New member | Healshape
5 May 2024Healshape is a regenerative medicine company with the mission to offer the enhanced option of self-tissue regeneration from patient’s own... View Article
Pherecydes Pharma strengthens its intellectual property with the first patent granted in Israel
Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that... View Article
Pherecydes Pharma strengthens its intellectual property with the first patent granted in Israel
5 May 2024Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that... View Article
OSE Immunotherapeutics provides an update on the first positive results and clinical development of CoVepiT, its multi-target T-cell anti-COVID vaccine
New clinical data confirm the good tolerance of CoVepiT and a very good level of T cell response in healthy... View Article
OSE Immunotherapeutics provides an update on the first positive results and clinical development of CoVepiT, its multi-target T-cell anti-COVID vaccine
5 May 2024New clinical data confirm the good tolerance of CoVepiT and a very good level of T cell response in healthy... View Article
Valneva signs purchase agreement with European Commission for its inactivated COVID-19 vaccine VLA2001
Valneva, a specialty vaccine company, today announced that it has signed an Advance Purchase Agreement (APA) with the European Commission... View Article
Valneva signs purchase agreement with European Commission for its inactivated COVID-19 vaccine VLA2001
5 May 2024Valneva, a specialty vaccine company, today announced that it has signed an Advance Purchase Agreement (APA) with the European Commission... View Article